The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
DDDr. Dereck Mush, MD, MBA
Sep 21
Orbis Medicines
Generative chemistry platform for orally bioavailable macrocyclic peptide drugs.
What they do
Orbis Medicines applies its nGen chemistry platform to synthesize orally bioavailable macrocycles aimed at intracellular protein-protein interactions. Led by CEO Morten Graugaard, it entered a multi-target drug discovery collaboration with Novo Nordisk worth up to 1.4 billion US dollars in September 2026.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- Oral macrocyclic peptides
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Copenhagen, Denmark
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- $90M raised
Notable investors: Novo Holdings.
Related on The Signal
An oral GLP-1 pill enters Phase 3, and the obesity race gets a new lane
DDDr. Dereck Mush, MD, MBA
Sep 4
The Oral Endocrine Pivot: Inside Sling Therapeutics' $123M Bet on Linsitinib
DDDr. Dereck Mush, MD, MBA
Sep 18
Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
DDDr. Dereck Mush, MD, MBA
Sep 14